STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Total
Balance at Feb. 28, 2017	$ 131,449	$ 118,609,079	$ (118,773,529)	$ (33,001)
Balance (in shares) at Feb. 28, 2017	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski, M.D., Ph.D. and related parties		319,268		319,268
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D		1,218,134		1,218,134
Net loss			(1,612,101)	(1,612,101)
Balance at Feb. 28, 2018	$ 131,449	120,146,481	(120,385,630)	(107,700)
Balance (in shares) at Feb. 28, 2018	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski, M.D., Ph.D. and related parties		477,718		477,718
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D		1,081,051		1,081,051
Net loss			(1,637,717)	(1,637,717)
Balance at Feb. 28, 2019	$ 131,449	$ 121,705,250	$ (122,023,347)	$ (186,648)
Balance (in shares) at Feb. 28, 2019	131,448,444